Strong sales and earnings growth for Novo Nordisk in 2014

30 January 2015

Danish diabetes care giant Novo Nordisk (NOV: N) posted financials this morning, showing that sales for full-year 2014 increased by 8% in local currencies to 88.8 billion Danish kroner ($13.42 billion; +6% in kroner).

Operating profit rose by 13% in local currencies 34.5 billion kroner (+10% in kroner). Net profit increased by 5% to 26.5 billion kroner, with diluted earnings per share rising by 8% to 10.07 kroner. Novo Nordisk’s shares edged up 1.3% to 303.80 kroner in early trading.

Operating profit for the fourth quarter rose to 9.16 billion kroner ($1.4 billion), above an average forecast of 8.75 billion kroner in a Reuters poll of analysts. Net income for the quarter climbed 8% to 6.53 billion kroner, beating the 6.45 billion-kroner average estimate of analysts surveyed by Bloomberg.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK